Beijing Wellso Pharmaceutical Co., Ltd.

Primary Objective: To compare the absorption rates and efficacy of acetaminophen-ibuprofen tablets (each tablet containing 250 mg acetaminophen and 125 mg ibuprofen) supplied by Beijing Huasu Pharmaceutical Co., Ltd., and acetaminophen-ibuprofen tablets (each tablet containing 250 mg acetaminophen and 125 mg ibuprofen; brand name: Advil DUAL ACTION With Acetaminophen) certified by Haleon US Holdings LLC in a healthy adult population under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary Objective: To evaluate the safety of acetaminophen-ibuprofen tablets (each tablet containing 250 mg acetaminophen and 125 mg ibuprofen) supplied by Beijing Huasu Pharmaceutical Co., Ltd., and acetaminophen-ibuprofen tablets (each tablet containing 250 mg acetaminophen and 125 mg ibuprofen; brand name: Advil DUAL ACTION With Acetaminophen) certified by Haleon US Holdings LLC in a healthy adult population under fasting and postprandial administration conditions.

Primary objective: To evaluate the bioequivalence of oxycodone hydrochloride sustained-release tablets (10 mg) developed and produced by Beijing Huasu Pharmaceutical Co., Ltd. and oxycodone hydrochloride sustained-release tablets (10 mg, OXYCONTIN®) produced by Purdue Pharma L.P. in Chinese patients with non-cancer chronic pain under fasting and fed conditions. Secondary objective: To evaluate the safety of oxycodone hydrochloride sustained-release tablets (10 mg) developed and produced by Beijing Huasu Pharmaceutical Co., Ltd. under fasting and fed conditions.

A single-center, randomized, open, two-dose, four-period completely repeated crossover, single-dose fasting and postprandial administration design was used to compare the differences in absorption extent and absorption rate between buspirone hydrochloride tablets (test preparation, strength: 10 mg) provided by Beijing Huasu Pharmaceutical Co., Ltd. and buspirone hydrochloride tablets (reference preparation, strength: 10 mg) certified by Teva Pharmaceuticals USA, Inc. in healthy Chinese people under fasting and postprandial administration conditions, and to evaluate the safety of buspirone hydrochloride tablets provided by Beijing Huasu Pharmaceutical Co., Ltd.